Connect with us

Hi, what are you looking for?

Monday, Feb 6, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Incannex appoints Eurofins to manufacture chewable nicotine and opioid treatment drug

The CannQuit-N and CannQuit-O products utilize CBD to reduce anxiety and cravings

Incannex appoints Eurofins to manufacture its chewable nicotine and opioid treatment drug
Photo by Theo0221 via Wikimedia Commons

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), an Australian cannabinoid and psychedelic medicine developer, has appointed Eurofins Scientific SE (EPA: ERF) to manufacture two medicated chewing gum products for treating nicotine and opioid addiction disorders.

Incannex announced the news on Friday, and the development follows a series of granted patents and patent applications for the two drugs that were transferred to the company in August from APIRx Pharmaceuticals following its acquisition by the Australian drug developer.

Eurofins will be undertaking the development, formulation and production of the CannQuit-N and CannQuit-O products which utilize CBD to help diminish anxiety and cravings in consumers.

Read more: Incannex receives positive feedback from FDA for its brain injury treatment drug

Read more: Incannex partners with Curia to accelerate production of IHL-216A

CannQuit-N has a combination of CBD and nicotine while CannQuit-O utilizes the cannabinoid and an “off-patent prescription opioid antagonist” which helps prevent dependency on the drug through its effect on receptors in the brain.

The products now being manufactured by Eurofins will be cGMP certified and used in clinical trials to assess their safety and efficacy prior to filing investigational new drug (IND) and new drug applications (NDA) with the FDA before eventual commercialization.

“Opioid and nicotine addiction are significant health problems and a major burden on health systems throughout the world. CannQuit products are designed to improve established therapies for the treatment of addiction. They do this by adding CBD, which is known to reduce cravings and anxiety which is critical for breaking the addiction cycle,” said Mark Bleackley, Chief Scientific Officer of Incannex.

Bleackley added that the products have strong potential to improve treatment outcomes for those who suffer from nicotine and opioid use disorders and that the company was excited to test the chewables in clinical trials following manufacture by Eurofins.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter









Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Psychiatrists can now prescribe MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression


The mining corporation has issued an apology for losing the device on a vast stretch of road in Western Australia


The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression

Alternative Energy

'It Matters To You' discusses the potential impact of the alternative energy source down under and around the globe